Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627634 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL19634252 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL14959447 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL2505132 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL9311281 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL19627636 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL8934285 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL9312524 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL30045327 | 0.91 | CHRM2 (0.43) | CHRM2CHRM1CHRM3GPR119HSD17B10 | |
| SCHEMBL21257391 | 0.90 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD17B10PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260001880-A1 | Bicyclic DGK Inhibitors | INCYTE CORPORATION | 2026-01-01 | — | — | US | disclosed |
| US-12466815-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | CARMOT THERAPEUTICS INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4638454-A1 | SUBSTITUTED IMIDAZO-BASED COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | Celgene Corporation (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4563199-A2 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12258340-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
| WO-2014144169-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-1626958-B1 | (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT 1F AGONISTS | LILLY CO ELI (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-7608629-B2 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608629-B2 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-5322852-A | Antitumor, antiprotozoa agents | CIBA-GEIGY CORP. (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0558443-A1 | O-Piperidyl-(3/4)-hydroxylamines and O-piperidyl-(3/4)-alkyl-hydroxylamines and their use as ornithine decarboxylase inhibitors | CIBA-GEIGY AG (CH) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | CHRM2 1884/4885CHRM1 1850/4885CHRM3 1647/4885 |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | CHRM2 573/4885CHRM1 574/4885CHRM3 265/4885 |
| US-12258340-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | CHRM2 3978/4885CHRM1 3749/4885CHRM3 2030/4885 |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | GLP1R, GCGR, GIPR | CHRM2 573/4885CHRM1 574/4885CHRM3 265/4885 |
| US-20260001880-A1 | Bicyclic DGK Inhibitors | DGKA, DGKG, DGKZ | CHRM2 3107/4885CHRM1 2367/4885CHRM3 2792/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | CHRM2 3041/4885CHRM1 3047/4885CHRM3 2742/4885 |
| US-12466815-B2 | Carboxamide compounds and uses thereof | PCK1, PHKG2, PHKG1 | CHRM2 4385/4885CHRM1 4363/4885CHRM3 3923/4885 |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | CHRM2 407/4885CHRM1 172/4885CHRM3 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.